The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Apr. 10, 2018
Filed:
Mar. 06, 2014
Applicants:
The General Hospital Corporation, Boston, MA (US);
The Brigham and Women's Hospital, Inc., Boston, MA (US);
Inventors:
Rizwan Haq, Boston, MA (US);
David E. Fisher, Newton, MA (US);
Hans Ragnar Widlund, Brookline, MA (US);
Assignees:
THE GENERAL HOSPITAL CORPORATION, Boston, MA (US);
THE BRIGHAM AND WOMEN'S HOSPITAL, INC., Boston, MA (US);
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/06 (2006.01); A61K 31/437 (2006.01); A61K 31/44 (2006.01); A61K 45/06 (2006.01); A61K 31/352 (2006.01); A61K 31/506 (2006.01); A61K 31/65 (2006.01); G01N 33/574 (2006.01); C12Q 1/68 (2018.01);
U.S. Cl.
CPC ...
A61K 31/437 (2013.01); A61K 31/06 (2013.01); A61K 31/352 (2013.01); A61K 31/44 (2013.01); A61K 31/506 (2013.01); A61K 31/65 (2013.01); A61K 45/06 (2013.01); C12Q 1/6886 (2013.01); G01N 33/5743 (2013.01); C12Q 2600/158 (2013.01);
Abstract
Embodiments described here are combinatorial compositions and methods using these compositions for treating melanomas having activated mutations. The compositions comprises combinations of inhibitors of a MAPK pathway, ERK inhibitors, EGFR inhibitors, oxidative phosphorylation (OXPHOS) inhibitors, inhibitors of B-Raf, mitochondrial inhibitors, c-KIT inhibitors, MEK inhibitors and tigecycline or a derivative thereof.